Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 2/2024

Open Access 15-04-2024 | Bevacizumab | Original Article

Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment

Authors: Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, Masahiro Toda, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki

Published in: Brain Tumor Pathology | Issue 2/2024

Login to get access

Abstract

Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under and after Bev therapy, including angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), placental growth factor (PLGF), fibroblast growth factor 2, and ephrin A2 (EphA2). Fifty-four GBM tissues, including 28 specimens from 14 cases as paired specimens from the same patient obtained in three settings: initial tumor resection (naïve Bev), tumors resected following Bev therapy (effective Bev), and recurrent tumors after Bev therapy (refractory Bev). Immunohistochemistry assessed their expressions in tumor vessels and its correlation with recurrent MRI patterns. PLGF expression was higher in the effective Bev group than in the naïve Bev group (p = 0.024) and remained high in the refractory Bev group. ANGPT2 and EphA2 expressions were higher in the refractory Bev group than in the naïve Bev group (p = 0.047 and 0.028, respectively). PLGF expression was higher in the refractory Bev group compared with the naïve Bev group for paired specimens (p = 0.036). PLGF was more abundant in T2 diffuse/circumscribe patterns (p = 0.046). This is the first study to evaluate angiogenic factors other than VEGF during effective and refractory Bev therapy in patient-derived specimens.
Appendix
Available only for authorised users
Literature
1.
Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed
2.
3.
Tamura R, Tanaka T, Miyake K et al (2016) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7:52423–52435CrossRefPubMedPubMedCentral
4.
5.
Yamamoto Y, Tamura R, Tanaka T et al (2017) “Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. Oncotarget 8:103890–103899CrossRefPubMedPubMedCentral
6.
7.
Casanovas O, HicklinDJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8;299–309.
8.
Tabouret E, Denicolai E, Delfino C et al (2016) Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. J Neuro Oncol 130(3):431–437CrossRef
9.
Okamoto S, Nitta M, Murayama T et al (2016) Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas. Brain Tumor Pathol 33:129–136CrossRefPubMed
10.
Batcheler TT, Gerstner ER, Emblem KE et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064CrossRef
11.
Saharinen P, Eklund Lauri, Alitalo Kari (2017) Therapeutic targeting of the angiopoietin–TIE pathway. Nat Rev Drug Discov 16(9): 635–661.
12.
Sundberg C, Kowanetz M, Brown LW et al (2002) Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82(4):387–401CrossRefPubMed
13.
Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563PubMed
14.
Asahara T, Chen T, Takahashi T et al (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83(3):233–240CrossRefPubMed
15.
16.
Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60CrossRefPubMed
17.
Reardon DA, Lassman AB, Schiff D et al (2018) Phase 2 and biomarker study of Trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer 124(7):1438–1448
18.
Affinito A, Quintavalle C, Esposito CL et al (2020) Targeting ephrin receptor tyrosine kinase A2 with a selective aptamer for glioblastoma stem cells. Mol Ther Nucleic Acid 20:176–185CrossRef
19.
20.
Qazi MA, Vola P, Venugopal C et al (2018) Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma. Cancer Res 78(17):5023–5037CrossRefPubMed
21.
Schneider K, Weyerbrock A, Doostkam S et al (2015) Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas. J Neurooncol 121(2):269–278CrossRefPubMed
22.
23.
DeLay M, Jahangiri A, Carbonell WS et al (2012) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18(10):2930–2942CrossRefPubMedPubMedCentral
24.
Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82(19):1684–1692CrossRefPubMed
25.
Mathieu V, Neve ND, Mercier ML et al (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10:1381–1392CrossRef
26.
Grossman R, Brastianos H, Blakeley JO et al (2014) Combination of anti-VEGF therapy and temozolomide in two-experimental human glioma models. J Neuro Oncol 116:59–65CrossRef
27.
28.
29.
Lee J, Park DY, Park DY et al (2014) Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci 55(4):2191–2199CrossRefPubMed
30.
Sawano A, Takahashi T, Tamaguchi S et al (1996) Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7(2):213–221PubMed
31.
Cubillo A, Galleago RA, Munoz M et al (2019) Dynamic angiogenic switch as predictor of response to chemotherapy-bevacizumab in patients with metastatic colorectal cancer. Am J Clin Oncol 42:56–59CrossRefPubMed
32.
Wykosky J, Gibo DM, Stanton C et al (2005) Eph A2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3(10):541–551CrossRefPubMed
33.
34.
Yao JC, Phan A, Hoff PM et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316–1323CrossRefPubMed
35.
Stratmann A et al (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153(5):1459–1466CrossRefPubMedPubMedCentral
36.
Crawford Y, Risau W, Plate KH (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 30:624–630CrossRefPubMed
37.
38.
Lund EL, Hog A, Olsen MWB et al (2004) Differential regulation of VEGF, HIF-1αand angiopoietin-1, -2, and -4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 108:833–838CrossRefPubMed
39.
40.
41.
Park HM, Shiva A, Cummings P et al (2023) Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res 83:1968–1983CrossRefPubMedPubMedCentral
42.
43.
Kloepper J, Riedemann L, Amoozgar Z et al (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 113(16):4476–4481CrossRefPubMedPubMedCentral
Metadata
Title
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
Authors
Taketo Ezaki
Toshihide Tanaka
Ryota Tamura
Kentaro Ohara
Yohei Yamamoto
Jun Takei
Yukina Morimoto
Ryotaro Imai
Yuki Kuranai
Yasuharu Akasaki
Masahiro Toda
Yuichi Murayama
Keisuke Miyake
Hikaru Sasaki
Publication date
15-04-2024
Publisher
Springer Nature Singapore
Published in
Brain Tumor Pathology / Issue 2/2024
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-024-00481-0

Other articles of this Issue 2/2024

Brain Tumor Pathology 2/2024 Go to the issue

Preface

Preface for Brain Tumor Pathology vol.41 issue 2

Original Article

Clinical and radiological features of intracranial ancient schwannomas: a single-institution, retrospective analysis

Correction

Correction: Beyond the WHO 2021 classification of the tumors of the central nervous system: transitioning from the 5th edition to the next

Review Article

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy

Original Article

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas

Rapid Short communication

Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature